Metoclopramide Lawsuit: Tardive Dyskinesia Claims and Settlements

A metoclopramide lawsuit — typically brought under the brand name Reglan — is a product liability claim alleging that long-term use of the gastrointestinal drug caused tardive dyskinesia or another serious neurological injury. Thousands of these cases have been filed since the FDA added a black box warning in 2009, most have now settled or been dismissed, and new claims face significant legal obstacles rooted in a pair of Supreme Court rulings that treat brand-name and generic manufacturers very differently.¹

The Injuries That Drove the Lawsuits

Metoclopramide blocks dopamine receptors in the brain and gut. That mechanism reduces nausea and speeds up gastric emptying, and it is also the reason the drug can cause tardive dyskinesia — a movement disorder marked by involuntary lip-smacking, tongue flicking, grimacing, and uncontrolled limb motion. The condition is often permanent, with no established cure.²

How often it happens has been contested. Older national guidelines cited prevalence between 1% and 15% in patients treated for at least three months. More recent work put the number far lower: a 2019 review estimated roughly 0.1% per 1,000 patient-years, and a 2026 claims-data analysis found an incidence around 0.37%.³⁴ Whatever the true rate, risk climbs with duration and cumulative dose, and elderly women, diabetics, and patients with liver or kidney failure face elevated danger.

Lawsuits have also alleged neuroleptic malignant syndrome, a rare reaction involving high fever, muscle rigidity, and altered mental status. A review of 20 reported NMS cases attributed to metoclopramide found that four ended in death.⁵ Parkinsonism has been alleged in some claims as well.⁶

The FDA’s February 2009 black box warning — the strongest safety alert available on a prescription label — stated that the risk of tardive dyskinesia rises with duration and total dose, told doctors to avoid treatment beyond 12 weeks in all but rare cases, and instructed them to discontinue the drug immediately if signs of tardive dyskinesia appeared.⁷ Filings surged after the warning issued. By 2011, Reglan and metoclopramide were described as the most litigated drug in the country.¹

Why Generic vs. Brand Name Matters for Your Claim

The single biggest factor in whether a metoclopramide lawsuit can succeed is whether the patient took the brand-name Reglan or a generic version. The Supreme Court split the two paths in a series of rulings.

Brand-Name: Wyeth v. Levine

In Wyeth v. Levine, decided March 4, 2009, the Court held 6–3 that federal drug approval does not shield brand-name manufacturers from state-law failure-to-warn claims. Manufacturers bear primary responsibility for their labels, and they can strengthen warnings on their own through the FDA’s “changes being effected” process.⁸⁹ Brand-name Reglan claims survived.

Generic: PLIVA v. Mensing

Two years later the Court went the other way. In PLIVA, Inc. v. Mensing, decided June 23, 2011 by a 5–4 vote, the Court ruled that federal law preempts state-law failure-to-warn claims against generic drug makers. The case directly involved two women, Gladys Mensing and Julie Demahy, who developed tardive dyskinesia after taking generic metoclopramide.¹⁰¹¹ Because federal rules require generic labels to be identical to the brand-name label, the Court found it impossible for generic makers to comply with both federal law and a state-law duty to warn more strongly. Justice Sotomayor’s dissent, joined by three others, called the result an “arbitrary distinction” that left generic drug consumers with no recourse.¹²

The effect on metoclopramide litigation was immediate. Most patients took the generic, so the ruling wiped out the majority of pending claims and led many firms to stop taking new generic cases.¹

Generic Design Defects: Mutual Pharmaceutical v. Bartlett

The Court extended Mensing in Mutual Pharmaceutical Co. v. Bartlett, decided June 24, 2013 in another 5–4 ruling. Design-defect claims against generic manufacturers are also preempted when they turn on the adequacy of warnings, and the Court rejected the argument that a manufacturer could dodge preemption by pulling the drug from the market.¹³¹⁴

The New Jersey Label-Delay Exception

One meaningful crack in generic preemption came out of New Jersey. In In re Reglan Litigation, decided August 22, 2016, the New Jersey Supreme Court held that failure-to-warn claims against generic manufacturers are not preempted when the generic maker failed to update its label promptly to match the FDA-approved brand-name labeling. The reasoning follows from Mensing itself: preemption depends on impossibility, and there is no impossibility if the generic manufacturer could have brought its label into line with the brand and simply did not. The decision let nearly 1,000 lawsuits consolidated in the state master complaint move forward.¹⁵

Where the Cases Went and What They Paid

Metoclopramide cases were never consolidated into a single federal multidistrict litigation. The Judicial Panel on Multidistrict Litigation refused consolidation in June 2009, so the cases were managed in state courts, primarily in Pennsylvania (more than 2,000 claims in the Philadelphia County Complex Litigation Center), New Jersey (centralized in 2010, dissolved by the state supreme court in November 2021), and California (Judicial Council Coordination Proceeding No. 4631 in San Francisco).¹⁶¹⁷¹⁸

The largest reported resolution came out of the California proceeding: a $250 million nationwide settlement covering roughly 5,000 cases across 18 venues, involving 16 pharmaceutical manufacturer defendant groups.¹⁸ In Philadelphia, Teva Pharmaceuticals and its subsidiaries reached a global settlement on February 6, 2018, resolving about 1,700 of the more than 2,000 pending claims; the financial terms were kept confidential.¹⁹ The remaining roughly 300 Philadelphia cases were later dismissed.⁶

Individual verdicts have varied. In 2007 a 69-year-old Rhode Island woman won a $2.95 million verdict against her prescribing physician, made up of $1.25 million in damages and $1.7 million in interest, after a pharmacist reportedly warned the doctor in 1995 about a possible movement disorder and the physician told her to keep taking the drug; she was not diagnosed with tardive dyskinesia until 2000. Reported individual awards otherwise have ranged from small sums to more than $1 million.¹

Can You Still File a Metoclopramide Lawsuit?

The mass tort has largely wound down. New Jersey’s centralized proceedings were dissolved in November 2021. Philadelphia ended with the 2018 Teva settlement and the later dismissals. Most law firms that once solicited Reglan clients no longer accept new cases.¹⁷¹

New filings are still technically possible, but the obstacles are steep:

Claims against generic manufacturers remain preempted under Mensing in most jurisdictions, unless the plaintiff can plead the New Jersey-style label-delay theory.
Claims against brand-name manufacturers are legally viable, but Wyeth transferred Reglan’s rights decades ago and the surviving defendants have mostly settled.
Statutes of limitations have knocked out late-filed cases. A Nebraska federal court dismissed one in 2016 involving claims filed more than a decade after the injury.¹

Attorneys who still evaluate potential claims generally look for patients who took metoclopramide for longer than three months, received a diagnosis of a neurological condition such as tardive dyskinesia, and can identify the brand-name manufacturer of the specific product they used.¹⁷

Claims Against Prescribing Doctors

A smaller share of metoclopramide litigation has been aimed at prescribers rather than manufacturers. A survey published in the American Journal of Gastroenterology in October 2014, drawing on the Westlaw database, identified 96 metoclopramide-related claims. Eighty-five (88%) targeted drug manufacturers, ten (about 11%) targeted prescribing physicians, and one targeted a pharmacist. Of the physician cases, five were medical malpractice claims and five were failure-to-warn claims.²⁰ The authors noted that with generic manufacturers now shielded by Mensing, plaintiff attention could shift toward the doctors who wrote the prescriptions. This route is separate from a product liability claim and turns on the individual prescriber’s conduct — how long the drug was prescribed, whether warning signs were acted on, and whether the prescription complied with the FDA’s 12-week limit.

If you believe you have a claim, act quickly. Statutes of limitations start running from the date of injury or diagnosis depending on the state, and the remaining defendants and viable legal theories are narrower than they were a decade ago.

1
Drugwatch. Reglan Lawsuits
2
National Center for Biotechnology Information. Metoclopramide
3
PubMed. Metoclopramide Safety Review
4
ResearchGate. Tardive Dyskinesia Risks and Metoclopramide Use Before and After US Market Withdrawal of Cisapride
5
Brieflands. Metoclopramide-Induced Neuroleptic Malignant Syndrome
6
FindLaw. Reglan Lawsuit Information
7
FDA. Metoclopramide Prescribing Information
8
Justia. Wyeth v. Levine, 555 U.S. 555
9
Oyez. Wyeth v. Levine
10
Justia. PLIVA, Inc. v. Mensing, 564 U.S. 604
11
SCOTUSblog. PLIVA, Inc. v. Mensing
12
Cornell Law Institute. PLIVA, Inc. v. Mensing, Dissent
13
Justia. Mutual Pharmaceutical Co. v. Bartlett, 570 U.S. 472
14
SCOTUSblog. Mutual Pharmaceutical Co. v. Bartlett
15
New Jersey Courts. In re Reglan Litigation, 228 N.J. 42
16
AboutLawsuits.com. Reglan Litigation Not Consolidated
17
Nolo. Reglan (Metoclopramide) Litigation
18
Mass Torts Made Perfect. Steven Skikos
19
Law360. Teva Exits Philly Reglan Mass Tort With Settlement
20
American Journal of Gastroenterology. A Survey of Lawsuits for Metoclopramide and Tardive Dyskinesia